CapsoVision, Inc (CV) stock
CVNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30383% above fair value
$6.03−0.24 (-3.83%)
Close on Nov 13, 2026Market cap $301.78MP/E –Yield –
CapsoVision r&d expenses
Research and development expenses are spending on new products and technology.
CapsoVision's R&D Expenses for the twelve months ending Sep 30, 2026 was $20.27M, up 29.1% year over year. For fiscal 2025 it was $18.31M, up 21.1% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.31M | +21.1% |
| FY2024 | Dec 31, 2024 | $15.12M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.80M | -21.1% |
| Q2 FY2026 | Jun 30, 2026 | $5.31M | +56.5% |
| Q1 FY2026 | Mar 31, 2026 | $4.44M | +42.7% |
| Q4 FY2025 | Dec 31, 2025 | $5.72M | +83.6% |
| Q3 FY2025 | Sep 30, 2025 | $6.09M | +34.7% |
| Q2 FY2025 | Jun 30, 2025 | $3.39M | -19.7% |
| Q1 FY2025 | Mar 31, 2025 | $3.11M | – |
| Q4 FY2024 | Dec 31, 2024 | $3.12M | – |
| Q3 FY2024 | Sep 30, 2024 | $4.52M | – |
| Q2 FY2024 | Jun 30, 2024 | $4.22M | – |
See a number that looks wrong?